Pupillary dilatation with single eyedrop mydriatic combinations.

We studied the mydiatic effect of three solutions containing a combination of two mydriatic drugs in 80 adult patients. The solutions tested were cyclopentolate HCl 0.5% with phenylephrine 2.5%, tropicamide 0.5% with phenylephrine 2.5%, and tropicamide 1.0% with phenylephrine 2.5%. We evaluated the effect of prior instillation of proparacaine 0.5% eyedrops. All three mydriatic combination solutions evaluated produced pupillary dilatation of about 7 mm within 60 minutes. Additional pupillary dilatation of 1 mm occurred when proparacaine was instilled before the mydriatic combination eyedrop. Mydriasis was resistant to bright light during indirect ophthalmoscopy in all patients. Pupils of younger patients dilated better than those of older patients, but sex and iris color were factors in the amount of pupillary dilatation obtained. Wide and sustained pupillary dilatation can be obtained for satisfactory indirect ophthalmoscopy by the instillation of one drop of proparacaine solution followed by a single drop of any of the three mydriatic combination solutions evaluated. By eliminating the need for multiple instillations of drugs, the use of a single eyedrop mydriatic combination is convenient in terms of time saved and also lessens the change of systemic drug toxicity.

Vascular hypotension and bradycardia following intraocular injection of acetylcholine during cataract surgery.

Two patients, an 80-year-old woman and a 70-year-old man, experienced profound systemic hypotension and bradycardia following intraocular acetylcholine administration during cataract surgery. When we compared these two cases with three previously published reports of similar occurrences, we found no common factors other than age that might have predisposed these patients to such complications. All five patients were in relatively good health and each received different combinations of premedication. This reaction occurred in two patients given local anesthesia, two given local anesthesia with intravenous sedation, and one given general anesthesia. Although a cause-and-effect relationship has not been proven, the suggestive temporal sequence of events indicated that all patients undergoing cataract surgery in which the use of intraocular acetylcholine is contemplated should be monitored by an anesthesiologist.

Organic tissue glue in the closure of cataract incisions.

We report our initial studies with a new organic tissue glue (Tisseel) in the closure of cataract incisions made in fresh cadaver eyes. We made two types of cataract incisions, posterior beveled and scleral pocket, and closed them with nylon sutures, glue, or a combination of both. The 11-mm posterior-beveled incision required eight nylon sutures, with or without glue, to maintain wound integrity at high intraocular pressures. We found the 7-mm and 11-mm pocket-type incisions to be essentially self-sealing and to leak only when posterior scleral lip pressure was applied. Once glue was added, even high posterior pressure did not disrupt the wound. This glue may thus present an alternative to suture closure of scleral pocket cataract incisions.

Organic tissue glue in the closure of cataract incisions in rabbit eyes.

We performed 7 mm scleral pocket cataract incisions in both eyes of ten rabbits. One eye of each rabbit was closed with one interrupted 10-0 nylon suture and organic tissue glue (Tisseel) and the other was closed with a conventional shoelace running 10-0 nylon suture. The eyes were examined clinically and histopathologically at various postoperative intervals. No difference in wound integrity was found between the two closures, but slightly more inflammation occurred in the eyes closed with glue than in those closed with sutures alone. Organic tissue glue may become an alternative method to suture closure of scleral pocket cataract incisions.

Cost-effective outpatient management of persons with heart failure.

Congestive heart failure remains one of the most prevalent and costly syndromes to treat throughout the world. In an era when cost-effective, quality, outcome-based care is a mandate, advanced practice nurse managed heart failure clinics propose a solution to this formidable problem. This paper examines a model of care based on self-monitoring utilized by an advanced practice nurse to effect the inter-related outcomes of readmission and cost of care.

"Tissue-drag" with polyglycolic acid (Dexon) and polyglactin 910 (Vicryl) sutures in strabismus surgery.

The new absorbable synthetic sutures, polyglycolic and (Dexon) and Polyglactin 910 (Vicryl), are excellent sutures for strabismus surgery, but they have a bothersome tendency to attract adjacent tissue (tissue-drag). This difficulty is found especially with the 5-0 size suture, less so with the 6-0 size suture, and minimally with the 7-0 size suture. The presence and number of short, stubbly, protuberant strands (hooklets) seen on the surface of these sutures under high magnification correlates with the lack of ease with which the sutures pass through tissue. Other factors involved in tissue-drag include the crevices between braids in these sutures and the fiber-tissue friction due to the innate nature of the suture materials. Sutures which pass with ease through tissue, such as catgut and nonabsorbable sutures, are seen to have smooth surfaces under high magnification. Coating the 5-0 and 6-0 Dexon and Vicryl sutures to smooth their surfaces and reduce tissue-drag was ineffective with isotonic saline solution, minimally to moderately effective with glycerine and with methylcellulose and polyvinyl alcohol solutions, but highly effective with peanut and sesame oils. Though tissue-passage of Dexon and Vicryl sutures was much improved by coating with oil and entirely satisfactory, it still was not quite as good as with catgut. Clinically, the oil did not compromise the knot security or ease of handling of the sutures. No unusual postoperative reaction was seen with the use of the oiled sutures. Although oiling the synthetic absorbable sutures at time of surgery is effective, we recommend that suture manufacturers reduce the tissue-drag of synthetic absorbable sutures either by smoothing the surface in the manufacturing process or by developing an absorbable coating applied to the sutures during manufacture.

Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.

BACKGROUND: Hospitalization of persons with congestive heart failure for recurrent heart failure or other complications is common. METHODS AND RESULTS: Male patients aged 18-75 with chronic heart failure were randomized in two sequential trials designed to study the efficacy of vasodilator therapy. Patients were evaluated every 3 months, and information regarding hospitalizations between visits was obtained from the patient, his family, and/or hospital records. Hospitalization data also were obtained for patients who had died between scheduled clinic visits. Hospitalizations were not recorded if a patient died during transit to the hospital or in the hospital emergency department before admission. In Vasodilator-Heart Failure Trial (V-HeFT) I, no significant difference in number of patients hospitalized or number of hospitalizations was noted among the treatment groups, although there was a trend for fewer and delayed cardiac hospitalizations in the hydralazine plus isosorbide dinitrate arm in which the survival was greater. In V-HeFT II, no difference in hospitalizations was apparent between the enalapril and hydralazine plus isosorbide dinitrate arms. Univariate predictors of hospitalization for all causes were reduced peak oxygen consumption (VO2) during exercise (p < 0.0001), reduced exercise duration (p < 0.0001), increased cardiothoracic ratio on chest radiograph (p < 0.0001), increased age (p < 0.03), and use of antiarrhythmic drugs (p < 0.013), whereas multivariate predictors were reduced peak VO2 (p < 0.0001), use of antiarrhythmic drugs (p < 0.015), and increased cardiothoracic ratio (p < 0.03). Univariate predictors of hospitalization for heart failure were peak VO2 (p < 0.0001), LVEF (p < 0.0001), reduced exercise duration (p < 0.0001), elevated cardiothoracic ratio (p < 0.0001), and elevated plasma norepinephrine (p < 0.0001). Multivariate predictors were exercise duration (p < 0.0001), LVEF (p < 0.04), elevated cardiothoracic ratio (p < 0.03), plasma norepinephrine (p < 0.0005), and coronary artery disease (p < 0.02). Time to first hospitalization, cause specific or overall, was considerably shorter for patients with baseline peak VO2 < 10 mL.kg-1 x min-1 compared with those with peak VO2 > 15 mL.kg-1 x min-1. CONCLUSIONS: Despite better survival in patients randomized to hydralazine plus isosorbide dinitrate compared with placebo and better survival in patients randomized to enalapril compared with hydralazine plus isosorbide dinitrate, no significant differences between the treatment groups were apparent in the incidence of hospitalization or time to first hospitalization for congestive heart failure, for cardiac reasons other than congestive heart failure, or for other causes. V-HeFT I and V-HeFT II data demonstrate no treatment effect on hospitalization, perhaps reflecting in part the effectiveness of the Veterans Affairs special heart failure clinics in dealing with worsening heart failure on an outpatient basis. Identification of predictors of hospitalization were similar in both studies.

Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group.

BACKGROUND: Two new questionnaires concerning the quality of life of patients with heart failure were used in a randomized, controlled trial to determine if the patients' perceptions of the effects of enalapril on their daily activities and sense of well-being were different from those of a group treated with hydralazine and isosorbide dinitrate. METHODS AND RESULTS: The questionnaires were completed at baseline and at 3 months, 6 months, and subsequently every 6 months during follow-up, which averaged 2.5 years (range, 0.5-5.7 years). Data from the questionnaires were reliable as indicated by correlation coefficients between repeated baseline scores of 0.88 and 0.87. Both treatment groups showed a progressive deterioration in quality of life as measured by both questionnaires. The questionnaire scores of the two treatment groups were not significantly different at any follow-up visit. Furthermore, there were no differences between treatments among subgroups defined by baseline questionnaire scores, peak oxygen consumption, ejection fraction, previous vasodilator use, and plasma norepinephrine concentration. CONCLUSIONS: Although several factors may limit the generalization of these results, the lack of a difference with regard to patients' quality of life is an important consideration for the evaluation of the relative therapeutic efficacy of these vasodilators.